CDK1 and neoplasm: Hence, it is possible the final consequence of the conflict between CDK1-mediated TAZ inactivation and TAZ-induced paclitaxel resistance is that when TAZ is overexpressed in tumor cells and limited CDK1 molecules are not sufficient to completely phosphorylate and inhibit TAZ, then activated TAZ will cause paclitaxel resistance [81].